PET: ¿linfoma activo?

Barra lateral del artículo

PDF
Publicado: 10-06-2006
DOI: https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v26i1.1172

Contenido principal del artículo

Tamara Kreindel
Servicio de Diagnóstico por Imágenes. Hospital Italiano de Buenos Aires

Resumen

.

Downloads

Download data is not yet available.

Detalles del artículo

Número

Vol. 26 Núm. 1 (2006): Revista del Hospital Italiano de Buenos Aires

Sección

Ateneo radiológico
Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Cómo citar

1.
Kreindel T. PET: ¿linfoma activo?. Rev Hosp Ital B.Aires [Internet]. 2006 Jun. 10 [cited 2026 Apr. 26];26(1):23-6. Available from: https://ojs.hospitalitaliano.org.ar/index.php/revistahi/article/view/1172

Referencias

Cairo MS, Raetz E, Lim MS, Davenport V,Perkins SL. Childhood and adolescent non-Hodgkin lymphoma: new insights in biology andcritical challenges for the future. Pediatr BloodCancer 2005; 45(6): 753-69. DOI: https://doi.org/10.1002/pbc.20342

Jerusalem G, Hustinx R, Beguin Y, Fillet G.Evaluation of therapy for lymphoma. Semin NuclMed 2005; 35(3): 186-96. DOI: https://doi.org/10.1053/j.semnuclmed.2005.02.004

Kazama T, Faria SC, Varavithya V,Phongkitkarun S, Ito H, Macapinlac HA. FDGPET in the evaluation of treatment for lymphoma:clinical usefulness and pitfalls. Radiographics2005; 25(1): 191-207. DOI: https://doi.org/10.1148/rg.251045045

Kostakoglu L, Agress H Jr, Goldsmith SJ.Clinical role of FDG PET in evaluation ofcancer patients. Radiographics 2003; 23(2):315-40; quiz 533. DOI: https://doi.org/10.1148/rg.232025705

Kostakoglu L, Goldsmith SJ. 18F-FDG PETevaluation of the response to therapy forlymphoma and for breast, lung, and colorectalcarcinoma. J Nucl Med 2003; 44(2): 224-39.

Kostakoglu L, Coleman M, Leonard JP, Kuji I,Zoe H, Goldsmith SJ. PET predicts prognosisafter 1 cycle of chemotherapy in aggressivelymphoma and Hodgkin’s disease. J Nucl Med2002; 43(8): 1018-27.

Mikhaeel NG, Hutchings M, Fields PA,O’Doherty MJ, Timothy AR. FDG-PET after twoto three cycles of chemotherapy predictsprogression-free and overall survival in high-gradenon-Hodgkin lymphoma. Ann Oncol 2005; 16(9):1514-23 DOI: https://doi.org/10.1093/annonc/mdi272

Pinkerton R. Continuing challenges in childhoodnon-Hodgkin’s lymphoma. Br J Haematol 2005;130(4): 480-8. DOI: https://doi.org/10.1111/j.1365-2141.2005.05598.x

Reinhardt MJ, Herkel C, Altehoefer C, Finke J,Moser E. Computed tomography and 18F-FDGpositron emission tomography for therapy controlof Hodgkin’s and non-Hodgkin’s lymphomapatients: when do we really need FDG-PET? AnnOncol 2005; 16(9): 1524-9. DOI: https://doi.org/10.1093/annonc/mdi271

Zijlstra JM, Hoekstra OS, Raijmakers PG,Comans EF, van der Hoeven JJ, Teule GJ, et al.18FDG positron emission tomography versus67Ga scintigraphy as prognostic test duringchemotherapy for non-Hodgkin’s lymphoma. BrJ Haematol 2003; 123(3): 454-62 DOI: https://doi.org/10.1046/j.1365-2141.2003.04617.x